

The Company takes no responsibility for the contents of this non-obligatory announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Foundation Biotech Limited
基石生物科技有限公司
(Incorporated in Hong Kong with limited liability)

VOLUNTARY ANNOUNCEMENT IN-DEPTH COLLABORATION WITH RAPHA GROUP FOR DEVELOPMENT

This announcement is made by Foundation Biotech Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Board of Directors (the “**Board**”) of the Company is pleased to announce that the Company has entered into an in-depth collaboration with Rapha Group (the “**Collaboration**”) for the joint research and development of innovative biomedical products and related technologies, representing a significant milestone in the Group's efforts to advance its product pipeline in high-end biomedical applications.

Under the Collaboration, the Parties will jointly formulate a research and development plan, establish a shared technical team, and leverage their respective expertise to accelerate the development and commercialisation of targeted biomedical products, creating long-term value for its shareholders.

For further information and updates on Foundation Biotech Limited, please visit our official website or contact our investor relations team.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company, and if they are in any doubt about their position, they should consult their professional adviser(s).

By order of the Board
Foundation Biotech Limited
Board of Directors

Hong Kong, 05 January 2026